EUVIMEDEUVIMED entdecken
CrossrefInfokarte

EMERGENCE OF CEFTAZIDIME-AVIBACTAM RESISTANCE IN ENTERO-BACTERALES AND PSEUDOMONAS AERUGINOSA

Alina Mehwish, Irim Iftikhar

Pakistan Journal of Pathology · 2023-12-29 · 34 (4) · 113-117

DOI: 10.55629/pakjpathol.v34i4.755 ↗
AbstractBibliografische Angaben

Abstract

Objective: The objective of this study is to determine the emergence of resistance to Ceftazidime-Avibactam (CAZ-AVI) by Enterobacterales and Pseudomonas aeruginosa in clinical isolates. Material and Methods: In this cross-sectional study (6-months) March-August 2022 Carbapenem resistant Enterobacterales were tested for Ceftazidime-Avibactam (30/20 µg, Oxoid Pvt Ltd) using Disk diffusion technique and enzymes were identified in resistant strains by Carbapenem Inactivation Method (mCIM, eCIM) as per CLSI M100 Guidelines 2022. Results: CAZ-AVI effectiveness has greatly decreased among Enterobacterales and P. aeruginosa isolates in recent past. Antimicrobial susceptibility testing results were interpreted using CLSI M100 document. Resistance against CAZ-AVI in Enterobacterales was found to be 80.8 % in E. coli and 72.1% in Klebsiella pneumonia isolates. This higher emergence is associated with CRE isolates majorly comprising MBLs in our country. Moreover, it has been observed that Metallo- β-lactamases mediated enzyme resistance is one of the major resistance patterns followed by serine carbapenemases. Conclusion: The high frequency of resistance 77% was observed against CAZ-AVI in CRE and in CRPA, the resistance is 80.1% respectively. In our country this tremendously increase in CAZ-AVI resistance is attributed to the existence of NDM in the region. Keywords: Carbapenem Resistant Enterobacterales (CRE), Metallo beta lactamases (MBLs), Carbapenem Resistant Pseudomonas aeruginosa (CRPA) Ceftazidime-Avibactam (CAZ-AVI), Modified Carbapenem Inactivation Method (mCIM), EDTA-modified Carbapenem Inactivation Method(eCIM), Multiple Drug Resistance (MDR)

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →